1. Home
  2. NDLS vs PLRX Comparison

NDLS vs PLRX Comparison

Compare NDLS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

N/A

Current Price

$13.74

Market Cap

68.7M

ML Signal

N/A

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

73.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
PLRX
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
73.7M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
NDLS
PLRX
Price
$13.74
$1.17
Analyst Decision
Hold
Hold
Analyst Count
1
4
Target Price
N/A
$2.67
AVG Volume (30 Days)
26.2K
437.8K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.97
EPS
N/A
N/A
Revenue
$495,089,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.37
N/A
52 Week Low
$0.47
$1.02
52 Week High
$19.00
$1.95

Technical Indicators

Market Signals
Indicator
NDLS
PLRX
Relative Strength Index (RSI) 42.95 55.13
Support Level $12.83 $1.12
Resistance Level $16.10 $1.26
Average True Range (ATR) 0.86 0.04
MACD -0.15 0.00
Stochastic Oscillator 15.92 57.87

Price Performance

Historical Comparison
NDLS
PLRX

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Share on Social Networks: